Literature DB >> 33679149

Validation of HPLC method for the determination of chemical andradiochemical purity of a 68Ga-labelled EuK-Sub-kf-(3-iodo-y-) DOTAGA.

Ayşe UĞur1, Şükrü Gökhan ElÇİ2, Doğangün YÜksel3.   

Abstract

The prostate-specific membrane antigen (PSMA) represents an ideal biomarker for molecular imaging. Various PSMA-targeted radioligands are available for prostate cancer imaging. In this study, labeling of PSMA I&T with 68Ga, as well as validation of the radiochemical purity of the synthesis product by reverse phase radio high-performance liquid chromatography (HPLC) method are intended. Since the standard procedure for the quality control (QC) was not available, definition of chemical and radiochemical purity of 68Ga-PSMA I&T was carried out according to the Q2 (R1) ICH guideline. The standard QC tests were analyzed with Scintomics 8100 radio-HPLC system equipped with a radioactivity detector. The method was evaluated in terms of linearity, precision and accuracy, LOQ, robustness parameters, and specificity. To assess the radiochemical and chemical purity of 68Ga-PSMA I&T, the developed method was validated to apply safely to patients. An excellent linearity was found between 1μg/mL and 30 μg/mL, with a limit of detection and limit of quantitation of 0.286 μg/mL and 0.866 μg/mL, respectively for 68Ga-PSMA I&T. The recovery was 96.8 ± 3.8%. The quality control of the final product was performed many times with validated radio-HPLC method and was found to comply with ICH requirements, thus demonstrating the accuracy and robustness of the method for routine clinical practice.
Copyright © 2021 The Author(s).

Entities:  

Keywords:  Imaging agents; quality control; radio-HPLC; radiochemical purity; radiolabeling

Year:  2021        PMID: 33679149      PMCID: PMC7925295          DOI: 10.3906/kim-2003-19

Source DB:  PubMed          Journal:  Turk J Chem        ISSN: 1300-0527            Impact factor:   1.239


  2 in total

1.  Development and Validation of Analytical Methods for Radiochemical Purity of 177Lu-PSMA-1.

Authors:  Pauline Orhon; Marie-Dominique Desruet; Marie Piquemal; Nicolas De Leiris; Loïc Djaileb; Jean-Philippe Vuillez; Pierrick Bedouch; Julien Leenhardt
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-24

2.  Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery.

Authors:  Else A Aalbersberg; Tammie T Cao; Martine M Geluk-Jonker; Jeroen J M A Hendrikx
Journal:  EJNMMI Radiopharm Chem       Date:  2022-09-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.